{"entity":{"id":"nct07181161","kind":"trial","name":"Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer","aka":["SEACLIFF"],"tldr":"This study tests a PARP inhibitor; the registry reports that it is recruiting.","summary":"The registry lists NCT07181161 as recruiting, last updated 2026-09-25. Enrolment is 283 planned participants, an estimate. Interventions: AZD0516, AZD9574. Primary measures include Module 1 and 2: Parts A and B: Number of participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Event of Special Interests (AESIs); Module 1 and 2: Part A: Number of participants with Dose Limiting Toxicities (DLTs). No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07181161","url":"https://clinicaltrials.gov/study/NCT07181161"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["palacaparib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07181161","phase":"1/2","setting":"A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0516 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Metastatic Prostate Cancer","sponsor":"AstraZeneca","participation":[{"nct":"NCT07181161","source":"https://clinicaltrials.gov/study/NCT07181161","fetchedAt":"2026-10-07T16:55:32.313Z","studySha256":"a614ff2ad7673bca9c06c83416172cade3cca597c4b288236e5051811e53c3f6","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-25","leadSponsor":"AstraZeneca","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"130 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":283,"enrolmentType":"ESTIMATED","siteCount":52,"recruitingSiteCount":22,"countries":["Brazil","China","France","Italy","Japan","Poland","South Korea","Spain","United Kingdom","United States"]}],"started":"2025-10-01","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07181161/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"palacaparib","kind":"drug","name":"Palacaparib","route":"/drugs/palacaparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}